NAGLREITER MedTech Incubator (www.nmddo.com) accelerates time to market with state of the art facilities, business systems, and a proven track record with industry exits and partnerships in Neurovascular, Robotics, Cardiovascular, Digital Health, End Effectors, Blades, Scopes, etc.
“We develop devices that will win in the marketplace through insights, coordinated and efficient systems, and proven models that are changing the innovation landscape. Our recipe is built to drive innovation efficiency while never wavering on our quality,” states Brett Naglreiter, CEO of NAGLREITER Medical Device Development Organization.
NAGLREITER has many development projects at various points of development. The objective is to build company / project value by developing superior technologies combined with strong business systems and best in class leadership.
Select ELEVATOR Companies
EMBA (www.embamedical.com)
A vascular occlusion platform technology with US and EU market clearance aiming for limited market release in Q2 2020
ICHOR (www.ichorvascular.com)
A vascular reperfusion technology with US market clearance aiming for limited market release and post market / real world data beginning Q2 2020
POSEYDON (www.poseydonmedical.com)
A next generation Neuro aspiration technology in mid stage development expecting to leap frog current aspiration “systems”
About NAGLREITER: NAGLREITER Medical Device Development Organization (MDDO) is a trusted partner for concept incubation, design, development, manufacturing, and engineering services within the MedTech industry. NAGLREITER prides itself on providing world-class services and employing a uniquely flexible business model to do so. NAGLREITER’s ‘The Right Path. With You’ business philosophy exemplifies the company’s commitment to partnering with clients in any way they require to yield the best possible outcomes.
Based in the Miami / Ft. Lauderdale area, NAGLREITER partners with medical device companies within the U.S. and abroad.
About iCHOR
iCHOR was founded by Interventional Radiologist Dr. Troy Long and industry veteran Tim Blair. They identified an opportunity to develop new technologies to address these large unmet needs in treating peripheral vascular occlusions. This collaboration has lead to the development of the iSWEEP platform technology that has converted the tried and true Fogarty balloon sweep technique from an open surgery to a simple, minimally-invasive endovascular procedure.
For further information please contact:
Tim Blair
Chief Executive Officer
[email protected]
